Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.

Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.

2.

Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice.

Shi JQ, Wang BR, Tian YY, Xu J, Gao L, Zhao SL, Jiang T, Xie HG, Zhang YD.

CNS Neurosci Ther. 2013 Nov;19(11):871-81. doi: 10.1111/cns.12144. Epub 2013 Jul 27.

PMID:
23889921
3.

Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L.

Neuron. 2007 Sep 6;55(5):697-711.

4.

Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.

Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L.

J Neurosci. 2011 Jan 12;31(2):700-11. doi: 10.1523/JNEUROSCI.4152-10.2011.

5.

Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease.

Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cissé M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L.

Nat Neurosci. 2008 Nov;11(11):1311-8. doi: 10.1038/nn.2213. Epub 2008 Oct 19.

6.

Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice.

Zhang MY, Zheng CY, Zou MM, Zhu JW, Zhang Y, Wang J, Liu CF, Li QF, Xiao ZC, Li S, Ma QH, Xu RX.

Neurobiol Aging. 2014 Dec;35(12):2713-25. doi: 10.1016/j.neurobiolaging.2014.06.009. Epub 2014 Jun 16.

PMID:
25044076
7.

Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease.

Corbett BF, Leiser SC, Ling HP, Nagy R, Breysse N, Zhang X, Hazra A, Brown JT, Randall AD, Wood A, Pangalos MN, Reinhart PH, Chin J.

J Neurosci. 2013 Apr 17;33(16):7020-6. doi: 10.1523/JNEUROSCI.2325-12.2013. Erratum in: J Neurosci. 2013 Jun 26;33(26):10934. Brown, Jon T [added]; Randall, Andrew D [added].

8.

Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.

Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ.

Cell. 2012 Apr 27;149(3):708-21. doi: 10.1016/j.cell.2012.02.046.

9.
10.

Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network.

Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L.

Neuron. 2010 Nov 4;68(3):428-41. doi: 10.1016/j.neuron.2010.10.020.

11.

Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease.

Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L.

J Neurosci. 2005 Oct 19;25(42):9694-703.

12.

Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.

PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. eCollection 2014.

13.

Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.

Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC.

J Alzheimers Dis. 2010;20 Suppl 2:S535-50. doi: 10.3233/JAD-2010-100342.

PMID:
20463404
14.

Epilepsy and cognitive impairments in Alzheimer disease.

Palop JJ, Mucke L.

Arch Neurol. 2009 Apr;66(4):435-40. doi: 10.1001/archneurol.2009.15. Epub 2009 Feb 9. Review.

15.

Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.

Durairajan SS, Liu LF, Lu JH, Chen LL, Yuan Q, Chung SK, Huang L, Li XS, Huang JD, Li M.

Neurobiol Aging. 2012 Dec;33(12):2903-19. doi: 10.1016/j.neurobiolaging.2012.02.016. Epub 2012 Mar 27.

PMID:
22459600
16.

A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.

Onishi T, Iwashita H, Uno Y, Kunitomo J, Saitoh M, Kimura E, Fujita H, Uchiyama N, Kori M, Takizawa M.

J Neurochem. 2011 Dec;119(6):1330-40. doi: 10.1111/j.1471-4159.2011.07532.x. Epub 2011 Nov 2.

17.

Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice.

Devi L, Ohno M.

Neurobiol Learn Mem. 2013 May;102:7-11. doi: 10.1016/j.nlm.2013.02.001. Epub 2013 Feb 13.

PMID:
23416036
18.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
19.

Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice.

Dubal DB, Zhu L, Sanchez PE, Worden K, Broestl L, Johnson E, Ho K, Yu GQ, Kim D, Betourne A, Kuro-O M, Masliah E, Abraham CR, Mucke L.

J Neurosci. 2015 Feb 11;35(6):2358-71. doi: 10.1523/JNEUROSCI.5791-12.2015.

20.

A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment.

Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K.

Neurobiol Dis. 2008 Jul;31(1):46-57. doi: 10.1016/j.nbd.2008.03.005. Epub 2008 Apr 7.

PMID:
18504134
Items per page

Supplemental Content

Write to the Help Desk